Microalbuminuria and Cardiovascular Disease

  • S. M. Thomas
  • G. C. Viberti
Chapter

Abstract

Classical risk factors for cardiovascular disease (CVD) mortality, such as cholesterol, blood pressure and smoking operate both in diabetic and non -diabetic subjects. However the absolute risk of cardiovascular death for men with diabetes, principally Type 2 diabetes, is up to three times higher and is progressively greater with each additional risk factor than in non-diabetic men [81]. Similarly the CVD mortality in a cohort of subjects with type 1 diabetes mellitus rises significantly in both men and women after the age of 30 reaching a two-fold excess, compared with non — diabetic subjects from the Framingham study [46].

Keywords

Coronary Heart Disease Diabetic Nephropathy Essential Hypertension Diabetic Subject Autonomic Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abraira, C, J. Colwell, F. Nuttall, C.T. Sawin, W. Henderson, J.P. Comstock, N.V. Emanuele, S.R. Levin, I. Pacold, and H.S. Lee. “Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.” Archives of Internal Medicine 157(1997): 181–188.PubMedCrossRefGoogle Scholar
  2. 2.
    Agewall, S., B. Persson, O. Samuelsson, S. Ljungman, H. Herlitz, Fagerberg, and B. “Microalbuminuria in treated hypertensive men at high risk of coronary disease. The Risk Factor Intervention Study Group.” Journal of Hypertension 11(1993):461–469.PubMedCrossRefGoogle Scholar
  3. 3.
    Allawi, J. and R.J. Jarrett. “Microalbuminuria and cardiovascular risk factors in type 2 diabetes mellitus.” Diabetic Medicine 7(1990): 115–118.PubMedCrossRefGoogle Scholar
  4. 4.
    Microalbuminuria Collaborative Study Group United Kingdom “Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study.” BMJ 306(1993a): 1235–1239.CrossRefGoogle Scholar
  5. 5.
    The Diabetes Control and Complications Trial Research Group. “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.” New England Journal of Medicine 329(1993b):977–986.CrossRefGoogle Scholar
  6. 6.
    The EUCLID Study Group. “Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria.” Lancet 349(1997):1787–1792.CrossRefGoogle Scholar
  7. 7.
    Bianchi, S., R. Bigazzi, G. Baldari, and V.M. Campese. “Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker.” American Journal of Hypertension 4(1991):291–296.PubMedGoogle Scholar
  8. 8.
    Bianchi, S., R. Bigazzi, G. Baldari, and V.M. Campese. “Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs.” American Journal of Medicine 93(1992):525–528.PubMedCrossRefGoogle Scholar
  9. 9.
    Bianchi, S., R. Bigazzi, G. Baldari, G. Sgherri, and V.M Campese. “Diurnal variations of blood pressure and microalbuminuria in essential hypertension.” American Journal of Hypertension 7(1994a):23–29.PubMedGoogle Scholar
  10. 10.
    Bianchi, S., R. Bigazzi, C. Valtriani, I. Chiapponi, G. Sgherri, G. Baldari, A. Natali, E. Ferrannini, and V.M. Campese. “Elevated serum insulin levels in patients with essential hypertension and microalbuminuria.” Hypertension 23(1994b):681–687.PubMedCrossRefGoogle Scholar
  11. 11.
    Bianchi, S., R. Bigazzi, A. Quinones Galvan, E. Muscelli, G. Baldari, N. Pecori, D. Ciociaro, E. Ferrannini, and A. Natali. “Insulin resistance in microalbummuric hypertension. Sites and mechanisms.” Hypertension 26(1995):789–795.PubMedCrossRefGoogle Scholar
  12. 12.
    Bigazzi, R., S. Bianchi, V.M Campese, and G. Baldari. “Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension.” Nephron 61(1992):94–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Bigazzi, R., S. Bianchi, D. Baldari, G. Sgherri, G. Baldari, and V.M. Campese. “Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors.” Hypertension 23(1994): 195–199.PubMedCrossRefGoogle Scholar
  14. 14.
    Bigazzi, R., S. Bianchi, R. Nenci, D. Baldari, G. Baldari, and V.M. Campese. “Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria.” Journal of Human Hypertension 9 (1995):827–833.PubMedGoogle Scholar
  15. 15.
    Bigazzi, R., S. Bianchi, G. Baldari, and V.M. Campese. “Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: role of insulin.” American Journal of Hypertension 9(1996):24–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Bigazzi, R. and S. Bianchi. “Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension.” Nephrology, Dialysis, Transplantation 10 Suppl 6(1995): 10–14.CrossRefGoogle Scholar
  17. 17.
    Borch-Johnsen, K. and S. Kreiner. “Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.” British Medical Journal Clinical Research Ed 294(1987):1651–1654.PubMedCrossRefGoogle Scholar
  18. 18.
    Cerasola, G., S. Cottone, G. Mule, E. Nardi, M.T. Mangano, G. Andronico, A Contomo, M. Li Vecchi, P. Galione, F. Renda, G. Piazza, V. Volpe, Lisi, A, L. Ferrara, N. Panepinto, and R. Riccobene. “Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.” Jouma/ of Hypertension 14(1996):915–920.CrossRefGoogle Scholar
  19. 19.
    Chaturvedi, N., J.M. Stephenson, and J.H. Fuller. “The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study.” Diabeteland, OD. Jorgensen, and C.E. Mogensen. “Microalbuminuria as predictor of increased mortality in elderly people.” BMJ 300 (1990):297–300.CrossRefGoogle Scholar
  20. 20.
    Damsgaard, E.M., A. Froland, O.D. Jorgensen, and CE. Mogensen. “Eight to nine year mortality in known non-insulin dependent diabetics and controls.” Kidney International 41 (1992):731–735.PubMedCrossRefGoogle Scholar
  21. 21.
    Damsgaard, E.M. and CE. Mogensen. “Microalbuminuria in elderly hyperglycaemic patients and controls.” Diabetic Medicine 3(1986):430–435.PubMedCrossRefGoogle Scholar
  22. 22.
    Deckert, T., B. Feldt-Rasmussen, K. Borch-Johnsen, T. Jensen, and A. Kofoed-Enevoldsen. “Albuminuria reflects widespread vascular damage. The Steno hypothesis.” Diabetologia 32(1989):219–226.PubMedCrossRefGoogle Scholar
  23. 23.
    Dineen, S. and H. Gerstein. “Microalbuminuria and mortality in NIDDM: a systematic overview of the literature.” Diabetes 44(1995):458(Abstract)Google Scholar
  24. 24.
    Earle, K. and Viberti G.C. “Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease.” Kidney International 45(1994):434–437.PubMedCrossRefGoogle Scholar
  25. 25.
    Earle, K.A, J. Walker, C. Hill, and Viberti G.C. “Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy.” New England Journal of Medicine 326(1992):673–677.PubMedCrossRefGoogle Scholar
  26. 26.
    Earle, K.A., M. Mattock, A. Morocutti, D. Aravanitis, and G.C. Viberti. “Lipoprotein(a) and atherosclerotic disease in insulin-dependent diabetic patients with declining glomerular filtration rate [letter].” Diabetic Medicine 13(1996a): 1071–1072.PubMedCrossRefGoogle Scholar
  27. 27.
    Earle, K. A, M. Mishra, A Morocutti, D. Barnes, E. Stephens, J. Chambers, and G.C. Viberti. “Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients.” Diabetologia 39(1996b):854–856.PubMedGoogle Scholar
  28. 28.
    Erley, C.M. and T. Risler. “Microalbuminuria in primary hypertension: is it a marker of glomerular damage?” Nephrology, Dialysis, Transplantation 9(1994): 1713–1715.PubMedGoogle Scholar
  29. 29.
    Fauvel, J.P., A. Hadj-Aissa, M Laville, G. Fadat, M. Labeeuw, P. Zech, and N. Pozet. “Microalbuminuria in normotensives with genetic risk of hypertension [letter].” Nepanscapillary Escape of albumin in Type 1 (insulin-dependent) diabetic patients with microalbuminuria.” Diabetologia 29(1986):282–286.CrossRefGoogle Scholar
  30. 30.
    Gatling, W., S. Tufail, M.A. Mullee, T.A. Westaoott, and R.D. Hill. “Mortality rates in diabetic patients from a community-based population compared to local age/sex matched controls.” Diabetic Medicine 14(1997):316–320.PubMedCrossRefGoogle Scholar
  31. 31.
    Gerber, L.M., C. Shmukler, and M.H. Alderman. “Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects.” Archives of Internal Medicine 152 (1992):373–377.PubMedCrossRefGoogle Scholar
  32. 32.
    Groop, P.H., Viberti G.C., T.G. Elliott, R. Friedman, A. Mackie, C. Ehnholm, M. Jauhiainen, and M.R. Taskinen. “Lipoprotein(a) in type 1 diabetic patients with renal disease.” Diabetic Medicine 11(1994):961–967.PubMedCrossRefGoogle Scholar
  33. 33.
    Gruden, G., P. Cavallo-Perin, M. Bazzan, S. Stella, V. Vuolo, and G. Pagano. “PAI-1 and Factor VII activity are higher in IDDM patients with microalbuminuria.” Diabetes 43(1994a):426–429.(Abstract)PubMedCrossRefGoogle Scholar
  34. 34.
    Gruden, G., M. Veglio, P. Cavallo-Perin, C. Olivetti, A. Mormile, Cassader, M, and G. Pagano. “Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria.” Hormone & Metabolic Research 26(1994b):489–490.CrossRefGoogle Scholar
  35. 35.
    Grunfeld, B., E. Perelstein, R. Simsolo, M Gimenez, and J.C. Romero. “Renal functional reserve and microalbuminuria in offspring of hypertensive parents.” Hypertension 15(1990):257–261.PubMedCrossRefGoogle Scholar
  36. 36.
    Haffner, S.M, M.P. Stern, M.K. Gruber, H.P. Hazuda, B.D. Mitchell Patterson, and JK. “Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects?” Arteriosclerosis 10(1990):727–731.PubMedCrossRefGoogle Scholar
  37. 37.
    Haneda, M, R. Kikkawa, M. Togawa, D. Koya, N. Kajiwara, T. Uzu, and Y. Shigeta. “High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus.” Journal of Diabetes & its Complications 6(1992):181–185.CrossRefGoogle Scholar
  38. 38.
    Jarrett, R.J., Viberti G.C., A. Argyropoulos, R.D. Hill, U. mortality in non-insulin-dependent diabetics.” Diabetic Medicine 1(1984):17–19.PubMedCrossRefGoogle Scholar
  39. 39.
    Jensen, J.S., K. Borch-Johnsen, G. Jensen, and B. Feldt-Rasmussen. “Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects.” Clinical Science 88(1995):629–633.PubMedGoogle Scholar
  40. 40.
    Jensen, T., E.A. Richter, B. Feldt-Rasmussen, H. Kelbaek, and T. Deckert. “Impaired aerobic work capacity in insulin dependent diabetics with increased urinary albumin excretion.” British Medical Journal Clinical Research Ed. 296(1988a):1352–1354.PubMedCrossRefGoogle Scholar
  41. 41.
    Jensen, T., S. Stender, and T. Deckert. “Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion.” Diabetologia 31(1988b): 142–145.PubMedCrossRefGoogle Scholar
  42. 42.
    Jensen, T., J. Bjerre-Knudsen, B. Feldt-Rasmussen, and T. Deckert. “Features of endothelial dysfunction in early diabetic nephropathy.” Lancer l(1989):461–463.CrossRefGoogle Scholar
  43. 43.
    Jones, S.L., C.F. Close, MB. Mattock, R. J. Jarrett, H. Keen, and Viberti G.C. “Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.” BM/ 298(1989):487–490.CrossRefGoogle Scholar
  44. 44.
    Kapelrud, H., H.J. Bangstad, K. Dahl-Jorgensen, K. Berg, and K.F. Hanssen. “Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.” BM/ 303(1991):675–678.CrossRefGoogle Scholar
  45. 45.
    Knowler, W.C., R.G. Nelson, and D.J. Pettitt. Diabetes, hypertension and kidney disease in the Pima Indians. In: The Kidney and Hypertension in Diabetes Mellitus. Edited by Mogensen, C. Boston, Dordrecht, London: Kluwer Academic, 1997, p.53.Google Scholar
  46. 46.
    Krolewski, A.S., E.J. Kosinski, J.H. Warram, O.S. Leland, E.J. Busick, A.C. Asmal, L.I. Rand, A.R. Christlieb, R.F. Bradley, and CR. Kahn. “Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.” American Journal of Cardiology 59(1987):750–755.PubMedCrossRefGoogle Scholar
  47. 47.
    Kuusisto, J., L. Mykkanen, K. Pyorala, and M. Laakso. “Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease.” Circulation 91(1995):831–837.PubMedCrossRefGoogle Scholar
  48. 48.
    Lahdenpera, S., P.H. Groop, M Tilly-Kiesi, T. Kuusi, T.G. Elliott, Viberti G.C., GC, and M.R. Taskinen. “LDL subclasses in IDDM patients: relation to diabetic nephropathy.” Diabetologia 37(1994):681–688.PubMedCrossRefGoogle Scholar
  49. 49.
    Lewis, E. J., L.G. Hunsicker, R.P. Bain, and R.D. Rohde. On behalf of The Collaborative Study Group. “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.” New England Journal of Medicine 329(1993): 1456–1462.Google Scholar
  50. 50.
    Ljungman, S. “Microalbuminuria in essential hypertension.” American Journal of Hypertension 3(1990):956–960.PubMedGoogle Scholar
  51. 51.
    Lopes de Faria, J.B., S.L. Jones, F. Macdonald, J. Chambers, and M.B. Mattock. “Sodium-lithium countertransport activity and insulin resistance in normotensive IDDM patients.” Diabetes 41(1992):610–615.CrossRefGoogle Scholar
  52. 52.
    Macleod, J.M., J. Lutale, and S.M. Marshall. “Albumin excretion and vascular deaths in NIDDM.” Diabetologia 38 (1995):610–616.PubMedCrossRefGoogle Scholar
  53. 53.
    Mattock, M., D.J. Barnes, Viberti G.C., H. Keen, D. Burt, J. Hughes, A.P. Fitzgerald, B. Sandhu, and P.G. Jackson. “Microalbuminuria and coronary heart disease in non — insulin dependent diabetes mellitus: an incidence study.” Submited for Publication (1998)(Abstract)Google Scholar
  54. 54.
    Mattock, MB., H. Keen, Viberti G.C., M.R. el-Gohari, T.J. Murrells, G.S. Scott, J.R. Wing, and P.G. Jackson. “Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients.” Diabetologia 31(1988):82–87.PubMedCrossRefGoogle Scholar
  55. 55.
    Mattock, M.B., N.J. Morrish, Viberti G.C., H. Keen, A.P. Fitzgerald, and G. Jackson. “Prospective study of microalbuminuria as predictor of mortality in NIDDM.” Diabetes 41 (1992):736–741.PubMedCrossRefGoogle Scholar
  56. 56.
    Messent, J.W., T.G. Elliott, R.D. Hill, R.J. Jarrett, H. Keen, and Viberti G.C. “Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study.” Kidney International 41(1992):836–839.PubMedCrossRefGoogle Scholar
  57. 57.
    Mogensen, CE. “Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.” New England Journal of Medicine 310(1984):356–360.PubMedCrossRefGoogle Scholar
  58. 58.
    Mogensen, CE., W.F. Keane, P.H. Bennett, G. Jerums, H.H. Parving, P. Passa, M.W. Steffes, G.E. Striker, and Viberti G.C. “Prevention of diabetic renal disease with special reference to microalbuminuria.” Lancet 346(1995): 1080–1084.PubMedCrossRefGoogle Scholar
  59. 59.
    Nannipieri, M., L. Rizzo, A. Rapuano, A. Pilo, G. Penno, and R. Navalesi. “Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients.” Diabetes Care 18(1995):l-9.CrossRefGoogle Scholar
  60. 60.
    Neil, A., M. Hawkins, M. Potok, M. Thorogood, D. Cohen, and J. Mann. “A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM.” Diabetes Care 16(1993):996–1003.PubMedCrossRefGoogle Scholar
  61. 61.
    Ng, L.L., C Dudley, J. Bomford, and D. Hawley. “Leucocyte intracellular pH and Na+/H+ antiport activity in human hypertension.” Journal of Hypertension 7(1989):471–475.PubMedCrossRefGoogle Scholar
  62. 62.
    Ng, L.L., J.E. Davies, M. Siczkowski, F.P. Sweeney, P.A. Quinn, B. Krolewski, and A.S. Krolewski. “Abnormal Na+/H+ antiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathy.” Journal of Clinical Investigation 93(1994):2750–2757.PubMedCrossRefGoogle Scholar
  63. 63.
    Nielsen, F.S., A.I. Voldsgaard, MA. Gall, P. Rossing, E. Hommel, P. Andersen, and H.H. Parving. “Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.” Diabetologia 36(1993):438–444.PubMedCrossRefGoogle Scholar
  64. 64.
    Parving, H.H., CE. Mogensen, H.A. Jensen, and P.E. Evrin. “Increased urinary albumin-excretion rate in benign essential hypertension.” Lancet 1(1974): 1190–1192.PubMedCrossRefGoogle Scholar
  65. 65.
    Parving, H.H., P. Jacobsen, K. Rossing, U.M Smidt, E. Hommel, and P. Rossing. “Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy.” Kidney International 49(1996): 1778–1782.PubMedCrossRefGoogle Scholar
  66. 66.
    Pedrinelli, R., V.D. Bello, G. Catapano, L. Talarico, F. Materazzi, Santoro, G, C. Giusti, F. Mosca, E. Melillo, and M. Ferrari. “Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients.” Arteriosclerosis & Thrombosis 13(1993):900–906.CrossRefGoogle Scholar
  67. 67.
    Pedrinelli, R., O. Giampietro, F. Carmassi, E. Melillo, G. Dell’Omo, G. Catapano, E. Matteucci, L. Talarico, M. Morale, F. De Negri, and et al. “Microalbuminuria and endothelial dysfunction in essential hypertension.” Lancet 344(1994):14–18.PubMedCrossRefGoogle Scholar
  68. 68.
    Pontremoli, R., V. Cheli, A. Sofia, A. Tirotta, M. Ravera, C. Nicolella, N. Ruello, C. Tomolillo, G.C. Antonucci, D. Bessarione, and et al. “Prevalence of micro- and macroalbuminuria and their relationship with other cardiovascular risk factors in essential hypertension.” Nephrology, Dialysis, Transplantation 10 Suppl 6(1995):6–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Pyorala, K., T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, and G. Thorgeirsson. “Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).” Diabetes Care 20(1997):614–620.PubMedCrossRefGoogle Scholar
  70. 70.
    Redon, X, M.A. Gomez-Sanchez, E. Baldo, M.C. Casai, M.L. Fernandez, Miralles, A, C. Gomez-Pajuelo, XL. Rodicio, and L.M. Ruilope. “Micro-albuminuria is correlated with left ventricular hypertrophy in male hypertensive patients.” Journal of Hypertension — Supplement 9(1991):S148–9.Google Scholar
  71. 71.
    Rossing, P., P. Hougaard, K. Borch- Johnsen, and H.H. Parving, “Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.” BM/ 313(1996):779–784.CrossRefGoogle Scholar
  72. 72.
    Rosskopf, D., R. Dusing, and W. Siffert. “Membrane sodium-proton exchange and primary hypertension.” Hypertension 21(1993):607–617.PubMedCrossRefGoogle Scholar
  73. 73.
    Ruilope, L.M., J.M. Alcazar, E. Hernandez, M. Praga, V. Lahera, and XL. Rodicio. “Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension.” Kidney International Supplement 45(1994):S171–3.Google Scholar
  74. 74.
    Ruilope, L.M. and XL. Rodicio. “Clinical relevance of proteinuria and microalbuminuria.” Current Opinion in Nephrology & Hypertension 2(1993):962–967.CrossRefGoogle Scholar
  75. 75.
    Ruilope, L.M. and XL. Rodicio. “Hypertension, atherosclerosis and microalbuminuria in ELSA. European Lacidipine Study of Atherosclerosis.” Blood Pressure Supplement. 4(1996): 48–52.PubMedGoogle Scholar
  76. 76.
    Sampson, M.J., J.B. Chambers, D.C. Sprigings, and P.L. Drury. “Regression of left ventricular hypertrophy with 1 year of treatment in type 1 diabetic patients with early.” Diabetic Medicine 8(1991):106–110.PubMedCrossRefGoogle Scholar
  77. 77.
    Sawicki, P.T. “Mortality in diabetic nephropathy: the importance of the QT interval.” Nephrology, Dialysis, Transplantation 11(1996):1514–1515.PubMedCrossRefGoogle Scholar
  78. 78.
    Schmitz, A. and M. Vaeth. “Microalbuminuria: a major risk factor in non insulin dependent diabetes. A 10 year follow up study of 503 patients.” Diabetic Medicine 5(1988): 126–134.PubMedCrossRefGoogle Scholar
  79. 79.
    Semplicini, A, M. Canessa, M.G. Mozzato, G. Ceolotto, M. Marzola, F. Buzzaccarini, P. Casolino, and A.C. Pessina. “Red blood cell Na+/H+ and Li+/Na+ exchange in patients with essential hypertension.” American Journal of Hypertension 2(1989):903–908.PubMedGoogle Scholar
  80. 80.
    Spring M.W., A. Raptis, X Chambers, and Viberti G.C. “Left ventricular structure and fonction are associated with microalbuminuria independently of blood pressure m Type II diabetes.” Diabetes 46(1997): 109A-A0426.(Abstract)Google Scholar
  81. 81.
    Stamler, X, O. Vaccaro, XD. Neaton, and D. Wentworth. “Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.” Diabetes Care 16(1993):434–444.PubMedCrossRefGoogle Scholar
  82. 82.
    Stehouwer, CD., H.R. Fischer, A.W. van Kuijk, B.C. Polak, and A.J. Donker. “Endothelial dysfunction precedes development of microalbuminuria in IDDM.” Diabetes 44(1995): 561–564.PubMedCrossRefGoogle Scholar
  83. 83.
    Steiner, G. “The dyslipoproteinemias of diabetes.” Atherosclerosis 110 Suppl(1994):S27–33. Titov, V.N., A.V. Tarasov, R.I. Sokolova, E.I. Volkova, and G.G. Arabidze. “A comparison of selective microproteinuria with histomorphology of the kidneys in patients with arterial hypertension.” Laboratomoe Delo (1989):43–48.CrossRefGoogle Scholar
  84. 84.
    Uusitupa, M.I., L.K. Niskanen, O. Siitonen, E. Voutilainen, and K. Pyorala. “Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects.” Diabetologia 36(1993):1175–1184.PubMedCrossRefGoogle Scholar
  85. 85.
    Viberti G.C., R.D. Hill, R.J. Jarrett, A. Argyropoulos, U. Mahmud, and H. Keen. “Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus.” Lancet 1(1982):1430–1432.PubMedCrossRefGoogle Scholar
  86. 86.
    Viberti G.C. “Outcome variables in the assessment of progression of diabetic kidney disease.” Kidney International — Supplement 45(1994):S121–4.Google Scholar
  87. 87.
    Winocour, P.H., J.O. Harland, J.P. Millar, M.F. Laker, and K.G. Alberti. “Microalbuminuria and associated cardiovascular risk factors in the community.” Atherosclerosis 93(1992):71–81.PubMedCrossRefGoogle Scholar
  88. 88.
    Wirta, O., A. Pastemack, J. Mustonen, and P. Laippala. “Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non -insulin dependent diabetic subjects.” Nephrology, Dialysis, Transplantation 12(1997):2612–2617.(Abstract)PubMedCrossRefGoogle Scholar
  89. 89.
    Yip, X, M.B. Mattock, A Morocutti, ML Sethi, R. Trevisan, and Viberti G.C. “Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.” Lancet 342(kson. “Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.” Lancet 2(1988):530–533.Google Scholar
  90. 90.
    Yudkin JS, Forrest RD, Jackson CA 1988. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet ii: 530–533.CrossRefGoogle Scholar
  91. 91.
    Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE, 1990. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ 300: 297–300.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • S. M. Thomas
    • 1
  • G. C. Viberti
    • 1
  1. 1.Department for Endocrinology, Diabetes and Metabolic MedicineGuy’s HospitalLondonUK

Personalised recommendations